Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges. However, three Motley Fool contributors think they can make the decisions ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Syngenta is continuing to grow its biologicals division with the recent acquisition of certain Novartis technologies.

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Novartis (NYSE:NVS) announced Friday that the European Medicines Agency (EMA), endorsed Fabhalta for the treatment of adults ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

THE last thing Lau remembered were the cries of his grade three pupils, shaking him and tapping his legs before he totally ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

Welcome to the PTC Therapeutics fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Today's conference is being recorded. I would now like to turn the conference over ...